The clinical significance of osteocalcin as a marker for advanced @entity263 was examined. Osteocalcin is produced by osteoblasts and is also detected in the blood. Its change is a good index of @entity66 and especially of the osteoblastic activity. In the present study, we examined the serum osteocalcin concentration of those @entity1 with @entity5 , especially @entity263 , who had been confirmed for multiple @entity79 by clinical examination. These @entity1 comprised an untreated group (15 cases) of @entity1 with @entity263 presenting confirmed @entity79 , and a group of @entity1 without @entity79 . The respective serum osteocalcin concentrations of these two groups were compared with 51 cases of prostate hypertrophy used as the control group. The findings revealed that the serum osteocalcin concentration demonstrated high values in the first group with a tendency toward lowering during treatment. Neither the latter group nor the control group showed high values. On the other hand, false-positive cases (8%), and false-negative cases (20%) were found. In the case of @entity79 , these results suggest that measurement of serum osteocalcin concentration is useful for clinical periodical observation about the activity of the bone metastatic focus.

[Clinical evaluation on serum osteocalcin in advanced XXXX @entity1 ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity66 :: ('MESH:D004194', 'Disease') :: ['osteometabolic diseases'] @entity5 :: ('MESH:D009369', 'Disease') :: ['urogenital tumor'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone-metastasis']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
